SetBone Medical closed an oversubscribed investment round of $1.6 million. Funds will support the next stage of development and initiation of a First in Human pilot study. The company has developed a novel bone cement for the treatment of spinal vertebrae fractures and other orthopedic procedures.
SetBone’s first product indication will be for the treatment of Vertebral Compression Fractures (VCF).
SetBone Medical has developed a new generation of bone cement to provide safer and more efficient treatment. SetBone’s proprietary bone cement does not contain any toxic monomers. It comes in a ready-to-use, prefilled cartridge for use “right out of the box.” SetBone’s cement allows extended working time, and its low exothermic reaction keeps cement curing temperature low preventing damage to surrounding tissue.
SetBone Medical closed an oversubscribed investment round of $1.6 million. Funds will support the next stage of development and initiation of a First in Human pilot study. The company has developed a novel bone cement for the treatment of spinal vertebrae fractures and other orthopedic procedures.
SetBone's first product indication will be for...
SetBone Medical closed an oversubscribed investment round of $1.6 million. Funds will support the next stage of development and initiation of a First in Human pilot study. The company has developed a novel bone cement for the treatment of spinal vertebrae fractures and other orthopedic procedures.
SetBone’s first product indication will be for the treatment of Vertebral Compression Fractures (VCF).
SetBone Medical has developed a new generation of bone cement to provide safer and more efficient treatment. SetBone’s proprietary bone cement does not contain any toxic monomers. It comes in a ready-to-use, prefilled cartridge for use “right out of the box.” SetBone’s cement allows extended working time, and its low exothermic reaction keeps cement curing temperature low preventing damage to surrounding tissue.
Copy to clipboard 
